Tacrolimus IPV Group Membership Does Not Consistently Track With Electronically Monitored or Self-reported Adherence in Adolescent and Young Adult Kidney Transplant Recipients
Authors:
- Cyd K. EatonCECyd K. Eaton
- Cozumel S. Md PruetteCPCozumel S. Md Pruette
- Kristin A. RiekertKRKristin A. Riekert
- Nazanin YousefzadehNYNazanin Yousefzadeh
- Ahna L. PaiAPAhna L. Pai
- Sandra Md AmaralSASandra Md Amaral
- Vikas R. DharnidharkaVDVikas R. Dharnidharka
- Bärbel KnäuperBKBärbel Knäuper
- Jodi M. SmithJSJodi M. Smith
- Susan L. FurthSFSusan L. Furth
- Bethany J. Md FosterBFBethany J. Md Foster
Open Access
- 12 May 2025
- journal article
- pediatric transplantation
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (6) , e1806
Abstract
Background.: High intrapatient variability (IPV) of tacrolimus trough concentrations (SD ≥ 2, coefficient of variation (CV%) ≥ 30) is associated with rejection and graft loss and may indicate nonadherence. However, the association between tacrolimus IPV and electronically monitored or self-reported adherence is unknown. Methods.: This secondary analysis of the TAKE-IT (Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial) compared electronically monitored and self-reported adherence between participants with high and low tacrolimus IPV among 103 adolescent and young adult kidney transplant recipients (mean age = 15.18 y, 59% male, 60% White, 65% >1-y posttransplant). Results.: Electronically monitored daily taking and timing adherence were not significantly associated with tacrolimus IPV group in binomial generalized linear mixed effects models: Participants with tacrolimus SD ≥ 2 or CV% ≥ 30 were no less likely to take each daily dose than those below these cutoffs (SD < versus ≥ 2: odds ratio [OR]; 0.84, 95% confidence interval [CI], 0.48-1.47; P = 0.54 and CV% < versus ≥ 30: OR, 0.72; 95% CI, 0.43-1.21; P = 0.22). Participants with tacrolimus SD ≥ 2 or CV% ≥ 30 were no less likely to take each daily dose on time than those below these cutoffs (SD < versus ≥ 2: OR, 0.70; 95% CI, 0.40-1.23; P = 0.21 and CV% < versus ≥ 30: OR, 0.68; 95% CI, 0.40-1.16; P = 0.15). Electronically monitored averages of doses taken, doses taken early/late, and differences from expected dose time were associated with tacrolimus IPV (P < 0.05) but were poor classifiers of IPV group membership (area under the curve < 0.70). Self-reported adherence was not associated with tacrolimus IPV. Conclusions.: Tacrolimus IPV group membership does not consistently track with behavioral adherence measures. Relying on tacrolimus IPV group membership may misidentify nonadherence in adolescent and young adult kidney transplant recipients.Keywords
This publication has 36 references indexed in Scilit:
- Monitoring drug adherenceTransplantation Reviews, 2015
- System for integrated adherence monitoring: Real‐time non‐adherence risk assessment in pediatric kidney transplantationPediatric Transplantation, 2012
- Association Between Age and Graft Failure Rates in Young Kidney Transplant RecipientsTransplantation, 2011
- Electronic Measurement of Medication Adherence in Pediatric Chronic Illness: A Review of MeasuresThe Journal of Pediatrics, 2011
- Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: A systematic reviewPediatric Transplantation, 2009
- Eliciting accurate reports of adherence in a clinical interview: development of the Medical Adherence Measure.2008
- Confounding: What it is and how to deal with itKidney International, 2008
- The Hawthorne Effect: a randomised, controlled trialBMC Medical Research Methodology, 2007
- Prospective Analysis of Nonadherence in Autoimmune Hepatitis: A Common ProblemJournal of Pediatric Gastroenterology and Nutrition, 2006
- Medication Adherence in Pediatric and Adolescent Liver Transplant RecipientsPediatrics, 2004